Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BRNS NASDAQ:GRDX NASDAQ:PULM NASDAQ:TXMD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBRNSBarinthus Biotherapeutics$0.60+0.3%$0.66$0.51▼$1.83$24.59M-0.4144,004 shs17,143 shsGRDXEntero Therapeutics$3.04-9.3%$4.71$1.08▼$6.93$21.02M1.8148,667 shs256,927 shsPULMPulmatrix$1.65-6.8%$1.52$1.16▼$5.80$6.03M1.922,134 shs14,873 shsTXMDTherapeuticsMD$2.06$2.05$0.99▼$2.95$23.84M0.5928,814 shs31,100 shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBRNSBarinthus Biotherapeutics0.00%-1.31%-16.27%-6.23%-68.48%GRDXEntero Therapeutics0.00%-20.42%-29.79%+33.92%+303,999,900.00%PULMPulmatrix0.00%-2.37%-1.20%+22.22%-72.59%TXMDTherapeuticsMD0.00%0.00%+1.48%-5.94%+71.67%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBRNSBarinthus Biotherapeutics$0.60+0.3%$0.66$0.51▼$1.83$24.59M-0.4144,004 shs17,143 shsGRDXEntero Therapeutics$3.04-9.3%$4.71$1.08▼$6.93$21.02M1.8148,667 shs256,927 shsPULMPulmatrix$1.65-6.8%$1.52$1.16▼$5.80$6.03M1.922,134 shs14,873 shsTXMDTherapeuticsMD$2.06$2.05$0.99▼$2.95$23.84M0.5928,814 shs31,100 shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBRNSBarinthus Biotherapeutics0.00%-1.31%-16.27%-6.23%-68.48%GRDXEntero Therapeutics0.00%-20.42%-29.79%+33.92%+303,999,900.00%PULMPulmatrix0.00%-2.37%-1.20%+22.22%-72.59%TXMDTherapeuticsMD0.00%0.00%+1.48%-5.94%+71.67%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBRNSBarinthus Biotherapeutics 2.00Hold$4.00564.45% UpsideGRDXEntero Therapeutics 0.00N/AN/AN/APULMPulmatrix 1.00SellN/AN/ATXMDTherapeuticsMD 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest PULM, BRNS, GRDX, and TXMD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/21/2026BRNSBarinthus Biotherapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)7/15/2026PULMPulmatrix Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)7/2/2026TXMDTherapeuticsMD Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/24/2026PULMPulmatrix Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/15/2026BRNSBarinthus Biotherapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/28/2026BRNSBarinthus Biotherapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/8/2026BRNSBarinthus Biotherapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)(Data available from 7/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBRNSBarinthus Biotherapeutics$14.97M1.64N/AN/A$1.82 per share0.33GRDXEntero Therapeutics$40K525.16N/AN/A$7.42 per share0.41PULMPulmatrix$7.81M0.77N/AN/A$2.45 per share0.67TXMDTherapeuticsMD$3.02M7.89$0.05 per share44.15$2.32 per share0.89Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBRNSBarinthus Biotherapeutics-$66.43M-$1.29N/AN/AN/AN/A-63.83%-48.77%8/6/2026 (Estimated)GRDXEntero Therapeutics-$6.39M-$1.88N/AN/AN/AN/A-49.81%-11.02%N/APULMPulmatrix-$5.16M-$1.23N/AN/AN/AN/A-107.84%-91.58%8/12/2026 (Estimated)TXMDTherapeuticsMD-$570K$0.0634.33N/AN/A5.34%0.32%0.23%8/17/2026 (Estimated)Latest PULM, BRNS, GRDX, and TXMD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/17/2026Q2 2026TXMDTherapeuticsMD-$5.50N/AN/AN/A$22.11 millionN/A8/6/2026Q2 2026BRNSBarinthus Biotherapeutics-$0.28N/AN/AN/AN/AN/A5/27/2026Q1 2026GRDXEntero TherapeuticsN/A-$0.82N/A-$0.82N/A$0.04 million5/15/2026Q1 2026PULMPulmatrixN/A-$0.32N/A-$0.32N/AN/A5/12/2026Q1 2026TXMDTherapeuticsMD-$6.1250$0.01+$6.1350$0.01$19.77 million$0.72 million5/1/2026Q4 2025GRDXEntero TherapeuticsN/A-$1.88N/A-$1.88N/AN/A4/30/2026Q1 2026BRNSBarinthus Biotherapeutics-$0.28-$0.14+$0.14-$0.14N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBRNSBarinthus BiotherapeuticsN/AN/AN/AN/AN/AGRDXEntero TherapeuticsN/AN/AN/AN/AN/APULMPulmatrixN/AN/AN/AN/AN/ATXMDTherapeuticsMDN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBRNSBarinthus BiotherapeuticsN/A6.056.05GRDXEntero TherapeuticsN/A0.160.16PULMPulmatrixN/A4.964.96TXMDTherapeuticsMDN/A3.113.11Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBRNSBarinthus Biotherapeutics25.20%GRDXEntero Therapeutics12.30%PULMPulmatrix11.84%TXMDTherapeuticsMD30.74%Insider OwnershipCompanyInsider OwnershipBRNSBarinthus Biotherapeutics8.50%GRDXEntero Therapeutics0.75%PULMPulmatrix0.62%TXMDTherapeuticsMD1.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBRNSBarinthus Biotherapeutics10740.85 million37.38 millionN/AGRDXEntero Therapeutics96.91 million6.86 millionN/APULMPulmatrix203.65 million3.63 millionNot OptionableTXMDTherapeuticsMD42011.57 million11.38 millionOptionablePULM, BRNS, GRDX, and TXMD HeadlinesRecent News About These CompaniesTherapeuticsMD Inc. stock underperforms Thursday when compared to competitors despite daily gainsJune 5, 2026 | marketwatch.comTherapeuticsMD Reports Quarterly Profit, Evaluates Strategic AlternativesMay 12, 2026 | tipranks.comTherapeuticsMD Announces First Quarter 2026 Financial ResultsMay 12, 2026 | businesswire.comTherapeuticsMD Inc. stock outperforms competitors on strong trading dayApril 6, 2026 | marketwatch.comTherapeuticsMD Narrows 2025 Loss, Advances Royalty StrategyApril 2, 2026 | theglobeandmail.comTherapeuticsMD Explains Brief Delay In Annual FilingApril 1, 2026 | tipranks.comTherapeuticsMD Announces Full Year 2025 Financial ResultsMarch 30, 2026 | finance.yahoo.comTherapeuticsMD Announces Full Year 2025 Financial ResultsMarch 30, 2026 | businesswire.comTherapeuticsMD (NASDAQ:TXMD) Director Tommy Thompson Buys 8,400 SharesDecember 30, 2025 | insidertrades.comTherapeuticsMD approves key proposals at annual meetingDecember 16, 2025 | msn.comTherapeuticsMD: Q3 Earnings SnapshotNovember 13, 2025 | timesunion.comTTherapeuticsMD Reports Q3 2025 Financial ResultsNovember 13, 2025 | msn.comTherapeuticsMD Announces Third Quarter 2025 Financial ResultsNovember 12, 2025 | businesswire.comTherapeuticsMD Reports Q2 2025 Financial ResultsAugust 12, 2025 | msn.comTherapeuticsMD: Q2 Earnings SnapshotAugust 12, 2025 | finance.yahoo.comTherapeuticsMD Announces Second Quarter 2025 Financial ResultsAugust 12, 2025 | businesswire.comTherapeuticsMD Inc. stock underperforms Wednesday when compared to competitors despite daily gainsJuly 16, 2025 | marketwatch.comMarlan D. Walker - TXMD | TherapeuticsMD Inc. - Wall Street JournalJune 29, 2025 | wsj.comMayne Pharma Files Legal Complaint Against TherapeuticsMDJune 1, 2025 | tipranks.comTherapeuticsMD Announces First Quarter 2025 Financial ResultsMay 13, 2025 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePULM, BRNS, GRDX, and TXMD Company DescriptionsBarinthus Biotherapeutics NASDAQ:BRNS$0.60 +0.00 (+0.32%) Closing price 07/24/2026 03:55 PM EasternExtended Trading$0.62 +0.02 (+3.49%) As of 07/24/2026 04:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer. It is also involved in the development of partnered candidates, such as AB-729-202, which is under phase 2a studies for the treatment of patients with chronic HBV infection; VTP-600, an immunotherapy candidate under phase 1 studies as a potential treatment for NSCLC in combination with standard of care treatment, chemotherapy, and pembrolizumab; VTP-500, a prophylactic vaccine product candidate under phase 1 studies to prevent infection and subsequent disease caused by the MERS coronavirus; and VTP-400, a prophylactic vaccine candidate under phase 1 studies to prevent shingles in adults aged 50 years and older. In addition, the company offers Vaxzevria (formerly VTP-900 and AZD1222), a prophylactic vaccine for the prevention of COVID-19 Infection. Further, it has license, research and development, and collaboration agreements with OUI, NIH, IMC, CanSino, CRUK; VOLT; and Arbutus. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Didcot, the United Kingdom.Entero Therapeutics NASDAQ:GRDX$3.04 -0.31 (-9.25%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$3.04 +0.00 (+0.16%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Entero Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of targeted and orally delivered therapies for the treatment of patients with gastrointestinal diseases. The company's pipeline candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides, currently under Phase 2 studies; and capeserod, a selective 5-HT4 receptor partial agonist under Phase 1 studies for the treatment of gastroparesis. It is also involved in the development of adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients, currently under Phase 2 studies for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis; and niclosamide, an oral small molecule with anti-inflammatory inhibitor therapy, currently under Phase 2 studies for the treatment of ulcerative proctitis and ulcerative proctosigmoiditis, as well as immune checkpoint inhibitor-associated colitis and diarrhea in metastatic cancer patients. The company was formerly known as First Wave BioPharma, Inc. and changed its name to Entero Therapeutics, Inc. in May 2024. Entero Therapeutics, Inc. was incorporated in 2014 and is based in Boca Raton, Florida.Pulmatrix NASDAQ:PULM$1.65 -0.12 (-6.78%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$1.50 -0.15 (-8.79%) As of 07/24/2026 06:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates. The company was founded in 2003 and is headquartered in Bedford, Massachusetts.TherapeuticsMD NASDAQ:TXMD$2.06 0.00 (0.00%) As of 07/24/2026 04:00 PM EasternTherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/20- 07/24 Telecom Earnings Reveal a Sector That Finally Looks Healthier AMD and Cerbras Create A New Blueprint For Hardware Intel Earnings Reveal Whether the Chip Selloff Created a Buy CrowdStrike’s Cerebras Deal Puts Its AI Security Strategy to the Test Defense Earnings Show Readiness Now and Modernization Ahead Freeport McMoRan Post-Earnings: Why Good Enough May Finally Be Good Enough Tesla Just Delivered Record Sales—So Why Did the Stock Sell Off? Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
